Statins as Antithrombotic Drugs
暂无分享,去创建一个
[1] S. Basili,et al. Immediate Antioxidant and Antiplatelet Effect of Atorvastatin via Inhibition of Nox2 , 2012, Circulation.
[2] G. Tognoni,et al. Association of aspirin use with major bleeding in patients with and without diabetes. , 2012, JAMA.
[3] K. Vadivel,et al. Structural biology of factor VIIa/tissue factor initiated coagulation. , 2012, Frontiers in bioscience.
[4] W. Ageno,et al. Aspirin for preventing the recurrence of venous thromboembolism. , 2012, The New England journal of medicine.
[5] D. Lauro,et al. Platelet Isoprostane Overproduction in Diabetic Patients Treated With Aspirin , 2012, Diabetes.
[6] P. Serruys,et al. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. , 2012, JACC. Cardiovascular imaging.
[7] D. Johns,et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. , 2012, The Journal of clinical investigation.
[8] P. Austin,et al. Statins and intracerebral hemorrhage: a retrospective cohort study. , 2012, Archives of neurology.
[9] P. Gorelick. Statin use and intracerebral hemorrhage: evidence for safety in recurrent stroke prevention? , 2012, Archives of neurology.
[10] Zhi-hong Ma,et al. Rho kinase inhibition by fasudil has anti-inflammatory effects in hypercholesterolemic rats. , 2011, Biological & pharmaceutical bulletin.
[11] C. Cannon,et al. Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies , 2011, Circulation.
[12] H. Hod,et al. Statins have an early antiplatelet effect in patients with acute myocardial infarction , 2011, Platelets.
[13] A. Plebani,et al. Inherited Human gp91phox Deficiency Is Associated With Impaired Isoprostane Formation and Platelet Dysfunction , 2011, Arteriosclerosis, thrombosis, and vascular biology.
[14] A. Bavry,et al. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. , 2010, Journal of the American College of Cardiology.
[15] R. McBane,et al. Inhibition of Platelet-Rich Arterial Thrombus In Vivo: Acute Antithrombotic Effect of Intravenous HMG-CoA Reductase Therapy , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[16] V. Pasceri,et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. , 2009, Journal of the American College of Cardiology.
[17] P. Libby,et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. , 2009, The New England journal of medicine.
[18] M. Vermeulen,et al. HEMORRHAGIC STROKE IN THE STROKE PREVENTION BY AGGRESSIVE REDUCTION IN CHOLESTEROL LEVELS STUDY , 2009, Neurology.
[19] D. Yellon,et al. Statins and cardioprotection--more than just lipid lowering? , 2009, Pharmacology & therapeutics.
[20] M. Hennerici,et al. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study , 2008, Neurology.
[21] K. Chu,et al. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti‐platelet activity of simvastatin , 2008, British journal of pharmacology.
[22] V. Fuster,et al. In vivo coronary plaque histology in patients with stable and acute coronary syndromes: relationships with hyperlipidemic status and statin treatment. , 2007, Atherosclerosis.
[23] Yu-Chieh Wang,et al. Pravastatin induces thrombomodulin expression in TNFα‐treated human aortic endothelial cells by inhibiting Rac1 and Cdc42 translocation and activity , 2007, Journal of cellular biochemistry.
[24] V. Pasceri,et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. , 2007, Journal of the American College of Cardiology.
[25] F. Violi,et al. Oxidative stress‐mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin , 2006, Journal of thrombosis and haemostasis : JTH.
[26] T. Villines,et al. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.
[27] M. Hennerici,et al. High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.
[28] C. Hennekens,et al. Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study). , 2006, The American journal of cardiology.
[29] H. Tillmanns,et al. Statins prevent NF-kappaB transactivation independently of the IKK-pathway in human endothelial cells. , 2006, Atherosclerosis.
[30] E. Braunwald,et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. , 2005, Journal of the American College of Cardiology.
[31] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[32] Zhiyong Lin,et al. Kruppel-Like Factor 2 as a Novel Mediator of Statin Effects in Endothelial Cells , 2005, Circulation.
[33] K. Mann,et al. Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[34] P. Reitsma,et al. Pravastatin reduces fibrinogen receptor gpIIIa on platelet‐derived microparticles in patients with type 2 diabetes , 2005, Journal of thrombosis and haemostasis : JTH.
[35] S. Yokoyama,et al. HMG-CoA Reductase Inhibitor Protects Against In Vivo Arterial Thrombosis by Augmenting Platelet-Derived Nitric Oxide Release in Rats , 2005, Journal of cardiovascular pharmacology.
[36] G. Garcı́a-Cardeña,et al. Kruppel-Like Factor 2 (KLF2) Regulates Endothelial Thrombotic Function , 2005, Circulation research.
[37] R. Lauro,et al. Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients , 2005, Circulation.
[38] K. Mann,et al. Statins and Blood Coagulation , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[39] 曲东锋. Stroke Prevention by Aggressive Reduction in Cholesterol Levels , 2004 .
[40] R. Collins,et al. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.
[41] J. Ioannidis,et al. Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. , 2003, Journal of the American College of Cardiology.
[42] M. Rosenfeld,et al. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. , 2003, Atherosclerosis.
[43] S. Horie,et al. Pitavastatin-Induced Thrombomodulin Expression by Endothelial Cells Acts Via Inhibition of Small G Proteins of the Rho Family , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[44] M. Endres,et al. Withdrawal of Statin Treatment Abrogates Stroke Protection in Mice , 2003, Stroke.
[45] A. Palazzuoli,et al. Time‐dependent effect of statins on platelet function in hypercholesterolaemia , 2002, European journal of clinical investigation.
[46] E. Istvan. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 2002, American heart journal.
[47] E. Arbustini,et al. Atorvastatin and Thrombogenicity of the Carotid Atherosclerotic Plaque: the ATROCAP Study , 2002, Thrombosis and Haemostasis.
[48] T. Lüscher,et al. Statin Prevents Tissue Factor Expression in Human Endothelial Cells: Role of Rho/Rho-Kinase and Akt Pathways , 2002, Circulation.
[49] H. White,et al. Withdrawal of Statins Increases Event Rates in Patients With Acute Coronary Syndromes , 2002, Circulation.
[50] M. Ezekowitz,et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. , 2001, JAMA.
[51] G. Lip,et al. Influence of pravastatin on lipoproteins, and on endothelial, platelet, and inflammatory markers in subjects with peripheral artery disease. , 2001, The American journal of cardiology.
[52] K. Mann,et al. Simvastatin Depresses Blood Clotting by Inhibiting Activation of Prothrombin, Factor V, and Factor XIII and by Enhancing Factor Va Inactivation , 2001, Circulation.
[53] A. Vignini,et al. Atorvastatin Increases ecNOS Levels in Human Platelets of Hyperlipidemic Subjects , 1999, Thrombosis and Haemostasis.
[54] R. Collins,et al. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.
[55] U. Laufs,et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.
[56] S. Basili,et al. Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia , 1997, The Lancet.
[57] E. Tremoli,et al. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[58] Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.
[59] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[60] G. Davı̀,et al. Inhibition of throm☐ane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia , 1994 .
[61] C. Esmon,et al. Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates. , 1993, The Journal of clinical investigation.
[62] L. Klein,et al. Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. , 1991, Journal of the American College of Cardiology.
[63] A. Wear. CIRCULATION , 1964, The Lancet.
[64] F. Santilli,et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. , 2011, Atherosclerosis.
[65] J. Farmer. High-dose atorvastatin after stroke or transient ischemic attack. , 2007, Current atherosclerosis reports.
[66] W. Howard. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .
[67] V. Pasceri,et al. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. , 2006, Journal of the American College of Cardiology.
[68] Franz Weidinger,et al. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. , 2006, American heart journal.
[69] S. Kelsey,et al. Impact of body mass index on outcomes of enhanced external counterpulsation therapy. , 2006, American heart journal.
[70] L. Lerman,et al. Statin effects beyond lipid lowering--are they clinically relevant? , 2003, European heart journal.
[71] E. A. Veselov. [Protection from mice]. , 1946, Gigiena i sanitariia.